CGT

56개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved56 programs
CGTLimited DatastaleProstate Cancer FoundationPhase 1

TmPSMA-02 CAR T Cells (TmPSMA-02 CAR T Cells)

Metastatic Castrate-Resistant Prostate Cancer (mCRPC) · PSMA

#PSMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 2Status Recruiting
CGTLimited DatastaleInge Marie SvanePhase 2

Young TIL (Young TIL)

Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer · Advanced Non-Small Cell Lung Cancer

#AdvancedNon-SmallCellLungCancer#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

Anti-NY ESO-1 T cell receptor (TCR, Anti-NY ESO-1 T cell receptor, Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells)

Metastatic Cancer; Metastatic Melanoma · Metastatic Cancer

#MetastaticCancer#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastalePromiCell Therapeutics, Inc.Phase 2

Anti-STEAP1 CAR T-cells (Anti-STEAP1 CAR T-cells)

Metastatic Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma · MET

#MET#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

Anti-Thyroglobulin mTCR PBL (Anti-Thyroglobulin mTCR PBL)

Metastatic Thyroid Cancer · Metastatic Thyroid Cancer

#MetastaticThyroidCancer#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

Anti-VEGFR2 CAR CD8 plus PBL (Anti-VEGFR2 CAR CD8 plus PBL)

Metastatic Cancer; Metastatic Melanoma · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleAlbert Einstein College of Medi…Phase 1

Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes (Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes)

HLA-A2 Positive Cells Present; Metastatic Malignant Neoplasm · HLA-A2 Positive Cells Present

#HLA-A2PositiveCellsPresent#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleCity of Hope Medical CenterPhase 1

Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes)

Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSorrento Therapeutics, Inc.Phase 1

CAR2 Anti-CEA CAR-T cells (CAR2 Anti-CEA CAR-T cells)

Metastatic Pancreatic Carcinoma · CEA

#CEA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleTceleron Therapeutics, Inc.Phase 1

CART-PSMA-TGFβRDN (CART-PSMA-TGFβRDN)

Metastatic Castration-resistant Prostate Cancer · PSMA

#PSMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

CART-meso (CART-meso)

Metastatic Pancreatic (Ductal) Adenocarcinoma; Epithelial Ovarian Cancer · Metastatic Pancreatic (Ductal) Adenocarc

#MetastaticPancreaticDuctalAdenoc#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

MSLN + MUC1 (EB-DNK101 dual-targeting CAR-NK cells, EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · Pancreatic Ductal Adenocarcinoma (PDAC)

#PancreaticDuctalAdenocarcinomaPD#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

CLDN18.2 + MUC1 (EB-DNK102 dual-targeting CAR-NK cells, EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · CLDN18.2

#CLDN182#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DUO-CAR-NK-CEA/GCC (EB-DUO-CAR-NK-CEA/GCC)

Colorectal Cancer; Metastatic Colorectal Adenocarcinoma · CEA

#CEA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-G3B7-NK dual-target CAR-NK cells (EB-G3B7-NK dual-target CAR-NK cells)

Advanced Hepatocellular Carcinoma (HCC); Metastatic Liver Cancer · Advanced Hepatocellular Carcinoma (HCC)

#AdvancedHepatocellularCarcinomaH#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-PT-CAR-NK-D (EB-PT-CAR-NK-D)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-PT-CAR-NK-S (EB-PT-CAR-NK-S)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EGFR/HER2 Dual-Target CAR-NK Cells (EGFR/HER2 Dual-Target CAR-NK Cells)

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma; Biomarker-positive EGFR/HER2- Expressing HNSCC · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting

2 / 3 pages

← PreviousNext →